Table 1 Demographics and clinical characterization of 260 patients with LC

Number

20

54

42

33

56

55

Age

 Year^a

69.30 ± 7.160

65.5 [61–68]

64 [59–67]

62.58 ± 10.90

63.5 [57–74]

66 [61–69]

 < 65

6 (30)

22 (40.74)

23 (54.76)

17 (51.52)

31 (55.36)

25 (45.45)

 ≥ 65

14 (70)

32 (59.26)

19 (45.24)

16 (48.48)

25 (44.64)

30 (54.55)

Sex

 Female

5 (25)

16 (29.63)

14 (33.33)

10 (30.30)

19 (33.93)

21 (38.18)

 Male

15 (75)

38 (70.37)

28 (66.67)

23 (69.70)

37 (66.07)

34 (61.82)

Histologic diagnosis

 NSCLC

19 (95)

53 (98.15)

38 (90.48)

28 (84.85)

53 (94.64)

45 (81.82)

 SCLC

1 (5)

1 (1.85)

3 (7.14)

5 (15.15)

2 (3.57)

9 (16.36)

 Others

0 (0)

0 (0)

1 (2.38)

0 (0)

0 (0)

1 (1.82)

 Unknown

0 (0)

0 (0)

0 (0)

0 (0)

1 (1.79)

0 (0)

Stage

 I/II

7 (35)

12 (22.22)

10 (23.81)

12 (36.36)

24 (42.86)

15 (27.27)

 III/IV

9 (45)

33 (61.11)

27 (64.29)

11 (33.33)

22 (39.29)

25 (45.45)

Unknown

4 (20)

9 (16.67)

5 (11.90)

10 (30.30)

10 (17.86)

15 (27.27)

Last treatment received < 3 mo

 Pre-treatment

4 (20)

12 (22.22)

14 (33.33)

10 (30.30)

8 (14.29)

0 (0)

 Chemotherapy

1 (5)

3 (5.56)

3 (7.14)

0 (0)

2 (3.57)

8 (14.55)

 Oral TKI or bevacizumab

2 (10)

11 (20.37)

6 (14.29)

3 (9.09)

5 (8.93)

20 (36.36)

 Immunotherapy

4 (20)

11 (20.37)

12 (28.57)

4 (12.12)

11 (19.64)

9 (16.6)

 Radiotherapy

0 (0)

1 (1.85)

2 (4.76)

5 (15.15)

4 (7.14)

5 (9.09)

 No systemic treatment

9 (45)

16 (29.63)

5 (11.90)

10 (30.30)

25 (44.64)

13 (23.64)

 Unknown

0 (0)

0 (0)

0 (0)

1 (3.03)

1 (1.79)

0 (0)

Clinical parameter

 WBC^a

7.253 ± 2.188

5.94 [4.85–7.25]

6.312 ± 1.825

6.11 [5.215–6.895]

6.620 [5.290–8.145]

5.24 [3.74–6.93]

 NEU^a

5.020 ± 2.300

3.615 [2.960–4.580]

3.955 [3.220–5.140]

3.565 [3.150–4.575]

4.235 [3.235–5.460)

3.38 [2.210–4.340]

 LYM^a

1.670 [1.210–1.945]

1.716 ± 0.514

1.490 [1.180–1.880]

1.748 ± 0.540

1.645 [1.265–1.980]

1.260 [0.930–1.990]